医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Japanese Pharmaceutical Industry Reviewed by GBI Research in In-Demand Study Now Available at MarketPublishers.com

2013年05月08日 AM01:25
このエントリーをはてなブックマークに追加


 

LONDON

Japan’s pharmaceutical industry, the world’s second largest, was worth USD 89 billion in 2011, representing 10 per cent of the global market share. However, the industry growth has been hindered by biennial drug price cuts in the recent past. Price revisions are constrained by the state health care budget, limiting the rise in drug product costs. Additionally, the gradual upsurge in market share and competition from generic drugs has sent the market value down, with the situation set to continue due to government policy that promotes their use.

Meantime, the regulatory reforms and government-industry cooperation have improved the global competitiveness of Japan’s pharmaceutical market. Coupled with a range of mergers, the industry is now composed of a slew of renowned multinationals. Takeda, Otsuka, Astellas, Daiichi Sankyo, and Eisai are the top five companies competing in the domestic pharma universe.

In-demand study “Japan Pharmaceutical Market Outlook – Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players” drawn up by GBI Research offers in-depth analysis and forecast of the pharmaceutical market in Japan. The report particularly covers:

  • assessment of the characteristics of the Japanese pharmaceutical market;
  • macroeconomic analysis of the country, with a focus on key economic parameters;
  • review of changing demographic landscape and implications on health economics and policy-making;
  • industry characteristics, including an overview of pricing policies, the regulatory landscape, new drug approval process and pharmaceutical supply chain in Japan;
  • analysis of the competitive landscape in Japan, including a discussion of the leading domestic companies and M&A
  • analysis of the drivers and barriers facing the Japanese pharmaceutical industry.

Report Details:

Title: Japan Pharmaceutical Market Outlook – Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players

Published: April, 2013

Pages: 97

Price: US$ 3,500.00

http://marketpublishers.com/report/life_sciences/pharmaceuticals/japan-pharmaceutical-market-outlook-deregulation-n-more-efficient-new-drug-approval-process-attract-foreign-investment-n-improve-competitiveness.html

Report Contents:

1 TABLE OF CONTENTS

1.1 List of Tables

1.2 List of Figures

2 INTRODUCTION

3 MARKET OVERVIEW

3.1 Introduction

3.2 Economic Landscape

3.3 Economic Indicators

3.3.1 Gross Domestic Product

3.3.2 GDP Composition by Sector

More in-demand market studies by GBI Research can be found at http://marketpublishers.com/members/gbiresearch/info.html

CONTACT

The Market Publishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax:
+44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Brightreeが初のHME向け患者アプリを発表
  • Brightree发布面向居家医疗器械的首个患者App
  • Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
  • ポットネットワーク・ホールディングスがSEC報告会社登録に基づきPCAOB監査人による完全な監査・レビュー済みの財務報告書を公表
  • Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc